Stockscreener 앱 받기
1.17
3.54%
0.04
전일 마감가:
$1.13
열려 있는:
$1.12
하루 거래량:
82,002
Relative Volume:
0.38
시가총액:
$4.25M
수익:
-
순이익/손실:
$-11.28M
주가수익비율:
-0.3887
EPS:
-3.01
순현금흐름:
$-9.78M
1주 성능:
-17.61%
1개월 성능:
-39.38%
6개월 성능:
-45.07%
1년 성능:
-80.72%
1일 변동 폭
$1.081
$1.2128
1주일 범위
$1.081
$1.45
52주 변동 폭
$1.081
$10.96
Ensysce Biosciences Inc Stock (ENSC) Company Profile
명칭
Ensysce Biosciences Inc
전화
(858) 263-4196
주소
7946 IVANHOE AVENUE, LA JOLLA
ENSC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
1.17 | 4.10M | 0 | -11.28M | -9.78M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.39 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.95 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.55 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
850.99 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.29 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ensysce Biosciences Inc 주식(ENSC)의 최신 뉴스
How Ensysce Biosciences Inc. stock reacts to Fed rate cutsJuly 2025 Action & Long-Term Investment Growth Plans - Улправда
EBIT per share of Ensysce Biosciences Inc. – OTC:ENSCW - TradingView — Track All Markets
Ensysce Biosciences’ Innovative Approach to Safer Opioid Use: A Clinical Study Update - MSN
ENSC enrolls first patient in critical phase 3 trial - MSN
Ensysce Biosciences initiates enrollment in Phase 3 trial of PF614 - MSN
Should You Buy Ensysce Biosciences After Share Sale? - StocksToTrade
Is Ensysce Biosciences a Hidden Gem? - timothysykes.com
Ensysce Biosciences enrolls first patient in phase 3 pain drug trial - Investing.com
Ensysce Biosciences enrolls first patient in phase 3 pain drug trial By Investing.com - Investing.com South Africa
Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid - Corsicana Daily Sun
Ensysce Biosciences (NASDAQ: ENSC) starts Phase 3 PF614 trial in abuse-deterrent opioid - Stock Titan
How Ensysce Biosciences Inc. stock performs in interest rate cyclesQuarterly Profit Review & Real-Time Buy Signal Notifications - Newser
Why Ensysce Biosciences Inc. stock attracts high net worth investorsIPO Watch & Free Weekly Chart Analysis and Trade Guides - Newser
Ensysce (NASDAQ: ENSC) secures MPAR overdose tech patent protection to 2042 - Stock Titan
Is Ensysce Biosciences Inc. stock near bottom after declineEarnings Beat & Weekly High Conviction Trade Ideas - Newser
Will Ensysce Biosciences Inc. stock outperform international peersProfit Target & Verified Stock Trade Ideas - Newser
Ensysce Biosciences (ENSC) Stock Analysis Report | Financials & Insights - Benzinga
Earnings Beat: Why Ensysce Biosciences Inc. stock is seen as undervalued2025 Volatility Report & Fast Gaining Stock Reports - moha.gov.vn
Is Ensysce Biosciences, Inc. overvalued or undervalued? - Markets Mojo
Ensysce Biosciences Inc. (ENSC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Ensysce Biosciences, Inc.Common Stock (NQ: ENSC - Markets Financial Content
[PRE 14A] Ensysce Biosciences, Inc. Preliminary Proxy Statement - Stock Titan
Will Ensysce Biosciences Inc. stock benefit from AI adoption2025 Volatility Report & Community Shared Stock Ideas - newser.com
Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach - The Joplin Globe
Ensysce (NASDAQ: ENSC) Receives FDA Agreement on PF614 Commercial Manufacturing Approach - Stock Titan
Why Ensysce Biosciences Inc. stock is popular among millennialsJuly 2025 Outlook & Growth Oriented Trade Recommendations - newser.com
FY2025 Earnings Estimate for ENSC Issued By Zacks Small Cap - Defense World
Real time social sentiment graph for Ensysce Biosciences Inc.New Guidance & Free Technical Pattern Based Buy Signals - newser.com
Is Ensysce Biosciences Inc. stock trading near support levelsTrade Exit Summary & Proven Capital Preservation Tips - newser.com
What the charts say about Ensysce Biosciences Inc. todayTrade Signal Summary & Weekly High Return Stock Forecasts - newser.com
How currency fluctuations impact Ensysce Biosciences Inc. stockWeekly Investment Recap & Technical Analysis for Trade Confirmation - newser.com
Momentum divergence signals in Ensysce Biosciences Inc. chart2025 Technical Overview & Expert Verified Stock Movement Alerts - newser.com
What catalysts could drive Ensysce Biosciences Inc. stock higherJuly 2025 Closing Moves & Weekly Top Gainers Alerts - newser.com
Ensysce Biosciences Secures $4M Financing for PF614 - The Globe and Mail
Will Ensysce Biosciences Inc. stock remain a Wall Street favorite2025 Year in Review & Short-Term Trading Opportunity Alerts - newser.com
[8-K] Ensysce Biosciences, Inc. Reports Material Event | ENSC SEC FilingForm 8-K - Stock Titan
Ensysce Biosciences : Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs - marketscreener.com
Ensysce Biosciences (NASDAQ: ENSC) closes $4M round, unlocking $16M for PF614 Phase 3 - Stock Titan
Ensysce Biosciences, Inc. announced that it has received $2.487 million in funding - MarketScreener
How high can Ensysce Biosciences Inc. stock goProduct Launch & Fast Exit/Entry Strategy Plans - newser.com
Why retail investors pile into Ensysce Biosciences Inc. stockJuly 2025 Weekly Recap & Trade Opportunity Analysis - newser.com
Ensysce Biosciences Inc (ENSC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.92%
0.17%
자본화:
|
볼륨(24시간):